Edition:
United States

AbbVie Inc (ABBV.N)

ABBV.N on New York Stock Exchange

91.53USD
16 Nov 2018
Change (% chg)

$1.39 (+1.54%)
Prev Close
$90.14
Open
$90.00
Day's High
$92.00
Day's Low
$89.20
Volume
2,262,826
Avg. Vol
1,536,715
52-wk High
$125.84
52-wk Low
$77.50

Chart for

About

AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology,... (more)

Overall

Beta: 1.65
Market Cap(Mil.): $132,702.00
Shares Outstanding(Mil.): 1,504.22
Dividend: 1.07
Yield (%): 4.85

Financials

  ABBV.N Industry Sector
P/E (TTM): 17.36 28.12 29.34
EPS (TTM): 5.08 -- --
ROI: 14.95 14.10 13.58
ROE: 421.19 15.67 15.11

Novartis launches third-to-market Remicade copy in Germany

ZURICH Novartis launched a copy of Johnson & Johnson's (J&J) inflammation-fighting Remicade in Germany on Thursday as the Swiss drugmaker aims to catch rival biosimilars that are already available in Europe's largest healthcare market.

Nov 15 2018

Novartis launches third-to-market Remicade copy in Germany

ZURICH, Nov 15 Novartis launched a copy of Johnson & Johnson's (J&J) inflammation-fighting Remicade in Germany on Thursday as the Swiss drugmaker aims to catch rival biosimilars that are already available in Europe's largest healthcare market.

Nov 15 2018

AbbVie sees hit to Humira sales from European competition

U.S. drugmaker AbbVie Inc on Friday lowered its forecast for overseas sales of its top-selling medicine, Humira, due to larger-than-expected pricing cuts because of new competition in Europe.

Nov 02 2018

UPDATE 3-AbbVie sees hit to Humira sales from European competition

Nov 2 U.S. drugmaker AbbVie Inc on Friday lowered its forecast for overseas sales of its top-selling medicine, Humira, due to larger-than-expected pricing cuts because of new competition in Europe.

Nov 02 2018

CORRECTED-UPDATE 2-AbbVie sees hit to Humira sales from European competition

Nov 2 U.S. drugmaker AbbVie Inc on Friday lowered its overseas sales forecast for its top-selling medicine, Humira, as it agreed to larger-than-expected price cuts due to new European competition.

Nov 02 2018

Humira biosimilars available at up to 80 percent discount in Europe: AbbVie

AbbVie Inc said on Friday rival biosimilar versions of its best-selling drug Humira were available in Europe at discounts ranging from 10 percent to 80 percent.

Nov 02 2018

Humira biosimilars available at up to 80 pct discount in Europe-AbbVie

Nov 2 AbbVie Inc said on Friday rival biosimilar versions of its best-selling drug Humira were available in Europe at discounts ranging from 10 percent to 80 percent.

Nov 02 2018

AbbVie expects double-digit earnings growth in 2019

AbbVie Inc said on Friday it was confident that its earnings would grow in the double digits in 2019, in spite of the launch of biosimilar versions of its best-selling rheumatoid arthritis drug Humira in the European Union.

Nov 02 2018

AbbVie expects double-digit earnings growth in 2019

Nov 2 AbbVie Inc said on Friday it was confident that its earnings would grow in the double digits in 2019, in spite of the launch of biosimilar versions of its best-selling rheumatoid arthritis drug Humira in the European Union.

Nov 02 2018

AbbVie lifts profit target after cancer drug powers third-quarter beat

Nov 2 AbbVie Inc beat Wall Street estimates for third-quarter profit and raised its earnings forecast for the year on Friday, driven by strong sales of blockbuster cancer medicine Imbruvica.

Nov 02 2018

Earnings vs. Estimates